Gilead’s Latest Stumble Quashes Last of Covid-19 Drug Gains

(Bloomberg) -- Gilead Sciences Inc. tumbled after failing to win regulatory approval of an experimental arthritis drug that had been touted as the biotech’s next $1 billion blockbuster, eroding the...